$2.210
-0.040 (-1.79%)Al cierre
Noticias de SNWV
Eventos de SNWV
SANUWAVE Health Inc Trading Resumes
SANUWAVE Health Inc trading resumes
SANUWAVE Health Inc Trading Halted Due to Volatility
SANUWAVE Health Inc trading halted, volatility trading pause
Sanuwave Health Q2 Revenue Expected to Reach $9.6M-$9.8M
Sanuwave Health announced that revenues for the second quarter of 2026 are expected to be in the range of $9.6M-$9.8M, above the high end of the revised guidance range of $8.5M-$9.5M provided in the company's press release dated June 16. Preliminary second quarter revenues represent a decrease of approximately 3%-5% from revenues of $10.1M in the second quarter of 2025. "Q2 came in a bit above the top of the range that we laid out back in June," said CEO Morgan Frank. "The business played out largely as we had forecast with capital sales facing headwinds from stress in our customer base and from the sale of used Ultramist systems in our market. Regarding the latter, as we discussed in our last release, Sanuwave will always seek to do what's best for the patients, so we've been working to help qualify, train, and support such new users and offering attractive trade-in terms such that units purchased used can be traded in for certified pre-owned systems that would carry a manufacturer's warranty. This program has been showing success so far. The good news in the quarter is that sales of consumable applicators set all time records for both unit sales and revenues, both by significant margins. We see this as an indication of both increasing interest and confidence in Ultramist as a wound care modality and, obviously, as consumables are the core of any razor-razorblade business, as a promising trend for the future. We look forward to speaking with you more about this when the company reports Q2 earnings in August."
Sanuwave Reports Q1 Revenue of $9.6M
Reports Q1 revenue $9.6M vs $9.3M last year. "The seemingly ubiquitous question in advanced wound care during Q1 was 'When is the turn coming and when will the recovery start?'" said CEO Morgan Frank. "Speaking for Sanuwave, the recovery appears to have begun in February and to have continued thereafter. Q1 started with a sort of "shock pause" as many seemed surprised that the changes in reimbursement for skin subs had actually taken effect, and this seems to have contributed to a very slow first month of the year which, in turn, had a large effect on the overall quarter. The market appeared somewhat frozen. But, at least from our standpoint, we see the ice starting to break up and the quarter got better each month. Q1 applicator sales were up 3% sequentially from Q4 and 15% year over year (again, suppressed by a very slow January) and very nearly eclipsed the all-time applicator revenue figure from Q3 2025. Unit volumes on consumables for Q1 2026 set a new all-time record by a significant margin which we take to be a good sign with regard to utilization recovering. This was driven by both new placements of systems and by activity picking back up at existing users. Revenues lagged unit growth as a function of lower pricing resulting from more of our applicators sales running through resellers and therefore being priced at wholesale. We're continuing to hire salespeople and to expand our reseller network. All in all, we exited the quarter with increasing optimism and a robust pipeline and we expect to see 2026 continue to get better from here."
Sanuwave Health Maintains FY26 Revenue View of $51M-$55M
Sanuwave Health backs FY26 revenue view $51M-$55M, one estimate $51.35M
Artículos relacionados
- How to Rebalance a Concentrated Stock Portfolio in 2026: Mag7 Drift, Tax-Aware Trims, and Practical Rebalance a concentrated stock portfolio in 2026: Mag7 drift risk, 5pp bands, tax-aware trims, RSP/IWM diversifiers, and single-name caps.
- Small Cap Stocks Investing Guide 2026: Russell 2000, Fed Hikes, and the Financing TradeSmall-cap stocks investing guide 2026: Russell 2000 vs S&P, IWM rate sensitivity, floating-rate debt, Fed hikes, valuation discounts, and a practical checklist.
- Santa Claus Rally and the Year-End Stock Market: Investor Guide for Late 2026Santa Claus rally explained: 7-day window stats since 1950, Nov–Dec seasonality, post-midterm 2026 setup, and a risk-managed year-end investing playbook.
Esta página es solo para investigación y no constituye asesoramiento de inversión. Los modelos pueden equivocarse. El rendimiento pasado no garantiza resultados futuros.